Premature ovarian insufficiency - novel hormonal approaches in optimizing fertility

• Published in: Gynecological endocrinology 2020-02, Vol.36 (2), p.162-165
• Main Authors: Dragojević Dikić, Svetlana, Vasiljević, Mladenko, Jovanović, Ana, Dikić, Srdjan, Jurišić, Aleksandar, Srbinović, Ljubomir, Vujović, Svetlana
• Format: Article
• Language: English
• Subjects: dehydroepiandrosterone; fertility; hormone therapy; melatonin; Premature ovarian insufficiency
• ISSN: 0951-3590; 1473-0766
• DOI: 10.1080/09513590.2019.1640203

Premature ovarian insufficiency (POI) is a delicate medical problem in young women. This condition is not unchangeable and permanent but is associated with intermittent and unpredictable ovarian activity, resulting in low conception rate. Over the period of 8 years, the evaluation of secondary amenorrhea was conducted in 90 patients below the age of 40 who wished to restore fertility. Having confirmed the diagnosis and investigated the etiology of POI, hormone replacement therapy was applied (sequential administration of estradiol and norethisterone acetate) in the first 30 patients (group A). Estrogen-progestogen therapy with daily supplementation of 25 mg of micronized oral dehydroepiandrosterone (DHEA) was conducted in 44 patients (group B), whereas a combined regime (estrogen-progestogen therapy, DHEA supplementation in daily dose of 25 mg, and melatonin supplementation in daily dose of 3 mg) was conducted in 16 patients (group C). In the course of our study, 16 pregnancies were realized (18% of all cases: 17% in group A; 18% in group B; 19% in group C) 6 to 20 months after the initiation of hormone therapy, and there have been 13 completed term pregnancies so far with normal fetal growth and development. We concluded that estrogen-progestogen therapy combined with DHEA and melatonin could optimize fertility and lead to successful pregnancy in POI patients.